The ACC recognizes the hard work and dedication of all Fellows in Training. Take the next step in your career by advancing to an FACC membership – the pinnacle of recognition in cardiology. This ...

SGLT2 inhibitors play an important role in preventing adverse cardiovascular events and improving outcomes in patients with heart failure, diabetes and chronic kidney disease. CardioSmart's updated ...

The following are key points to remember from an international consensus on cardiopulmonary resuscitation (CPR) and emergency cardiovascular care science with treatment recommendations: ...

An expert panel report, one of three in a special series published in JACC: CardioOncology, provides a review of the current evidence for the cardiovascular care of patients before cardiotoxic cancer ...

Petersen SR, Bonnesen K, Grove EL, Pedersen L, Schmidt M. The authors conducted a nationwide cohort study of 51,794 patients with VTE who had initiated OAC therapy between 2012-2022. Time-dependent ...

Preventing, detecting and managing cancer therapy-related cardiovascular toxicity (CTR-CVT) is a clear objective during cancer treatment. An expert panel report published in JACC: CardioOncology ...

Showcase your cutting-edge simulator in the ACC.25 Cardio Sim Creator Competition and pave the way for advancements in simulation-based education. Whether you've developed a procedural trainer, a ...

A unique blend of forum and network, the Cardiovascular (CV) Team Member Section and Leadership Council is advancing ACC's efforts to identify and address gaps in areas of professional importance to ...

New science presented at AHA 2024 and simultaneously published in JACC: Advances provide insights on emerging topics such as the use of artificial intelligence (AI)-enabled left atrial (LA) volumetry ...

Nonsustained ventricular tachycardia (NSVT) is roughly as common in athletes as in the general population, and is more frequently associated with structural abnormalities in those with higher burden ...

In this special edition of Eagle’s Eye View, Dr. Eagle looks at the most important trials presented at the recent AHA scientific sessions: 1) BROAD, exploring more intensive blood pressure control; 2) ...